论文部分内容阅读
摘要目的本研究采用放射基因风险评分(RRS)方法(以往定义为具有预测意义的生物标志物),评估该方法能否对术前经贝伐单抗治疗的转移性肾细胞癌(mRCC)病人进行影像学无进展生存期(rPFS)分层。方法本研究得到伦理委员会批准。放射基因风险评分(RRS)的前瞻性成像分析基于
Abstract Objectives In this study, a radiosensitive risk score (RRS) method (previously defined as a predictive biomarker) was used to assess whether this method is effective against preoperatively metastatic renal cell carcinoma (mRCC) patients treated with bevacizumab Imaging progression-free survival (rPFS) stratification. Methods This study was approved by Ethics Committee. Prospective imaging analysis of Radiation Gene Risk Score (RRS) was based on